IV 
115TH CONGRESS 
2D SESSION 
H. RES. 960 
Expressing the sense of the House of Representatives in support of HIV 
pre-exposure prophylaxis research, education, and usage, and addressing 
the barriers to receiving this treatment, especially for communities of 
color, gay and bisexual men, and transgender people. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 25, 2018 
Mrs. WATSON COLEMAN (for herself, Ms. CLARKE of New York, Mr. GRI-
JALVA, Ms. NORTON, and Mr. POCAN) submitted the following resolution; 
which was referred to the Committee on Energy and Commerce 
RESOLUTION 
Expressing the sense of the House of Representatives in 
support of HIV pre-exposure prophylaxis research, edu-
cation, and usage, and addressing the barriers to receiv-
ing this treatment, especially for communities of color, 
gay and bisexual men, and transgender people. 
Whereas pre-exposure prophylaxis (PrEP) is medication that 
is used to help prevent the contraction of the human im-
munodeficiency virus (HIV); 
Whereas currently PrEP is a daily pill consisting of two 
medications, tenofovir and emtricitabine, that an indi-
vidual can take orally, which can greatly reduce the likeli-
hood of contracting HIV; 
VerDate Sep 11 2014 
01:16 Jun 26, 2018
Jkt 079200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR960.IH
HR960
lotter on DSKBCFDHB2PROD with BILLS
•HRES 960 IH 
Whereas if used properly, PrEP can reduce the risk of con-
tracting HIV from sex by up to 99 percent and can re-
duce the risk of contracting HIV among people who in-
ject drugs by more than 70 percent; 
Whereas PrEP can be used by anyone who currently does not 
have HIV and is at substantial risk of contracting the 
virus; 
Whereas quarterly screening for sexually transmitted infec-
tions (STI), including testing at extra-genital sites, sig-
nificantly increases detection of gonorrhea, chlamydia, 
and syphilis for those on PrEP, providing opportunities 
for prompt treatment, partner therapy, and prevention of 
STI-related morbidity; 
Whereas the Centers for Disease Control and Prevention’s 
HIV/AIDS prevention efforts are under the direction of 
the National Center for HIV/AIDS, Viral Hepatitis, 
STD, and TB Prevention whose mission includes pre-
venting HIV infection and reducing the incidence of HIV- 
related illness and death; 
Whereas the Centers for Disease Control and Prevention is 
conducting projects such as Project PrIDE and Project 
THRIVE which work to support State and local health 
department demonstration projects for providing com-
prehensive HIV prevention and care services for the 
LGBTQA community and specific communities of color; 
Whereas the Centers for Disease Control and Prevention re-
ported that approximately 500,000 African Americans 
and nearly 300,000 Latinos across the Nation could have 
potentially benefitted from PrEP based on CDC clinical 
guidelines in 2015–2016, but only 7,000 prescriptions 
VerDate Sep 11 2014 
01:16 Jun 26, 2018
Jkt 079200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR960.IH
HR960
lotter on DSKBCFDHB2PROD with BILLS
•HRES 960 IH 
were filled for African Americans and only 7,600 for 
Latinos during the same time period; 
Whereas Emory University’s Rollins School of Public Health 
used a national prescription database to estimate that 
61,298 people were using PrEP as of 2017, the majority 
of whom were White men, over the age of 24, and living 
in the Northeast, meaning that the medication is not 
reaching communities of color who are at higher risk of 
contracting HIV; 
Whereas more work needs to be done to further educate the 
public and health care professionals about PrEP to ad-
dress this disparity; 
Whereas the United States should continue to commit itself 
to the goal of eradicating HIV; and 
Whereas it is more cost effective to prevent diseases than to 
treat them: Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) recognizes the value of pre-exposure prophy-
laxis (PrEP) as an effective prevention tool in com-
bating human immunodeficiency virus (HIV); 
(2) supports the research, education, and usage 
of the current PrEP and encourages the medical 
community, both private and public, to continue 
working on creating new PrEP medications to re-
duce the spread of HIV; 
(3) calls on Congress to increase funding to ex-
isting programs that are working to educate the 
public and healthcare professionals about PrEP, how 
VerDate Sep 11 2014 
01:16 Jun 26, 2018
Jkt 079200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR960.IH
HR960
lotter on DSKBCFDHB2PROD with BILLS
•HRES 960 IH 
it works, how and when to prescribe these medicines, 
and how individuals who qualify to take the regimen 
can obtain it; and 
(4) calls on the Secretary of Health and 
Human Services to— 
(A) conduct a departmentwide review on 
the outreach efforts of all HIV prevention pro-
grams in agencies such as the Health Resources 
and Service Administration, the Centers for 
Disease Control and Prevention, the Substance 
Abuse and Mental Health Services Administra-
tion, and others to ensure that they are con-
ducting effective outreach, especially to commu-
nities of color, gay and bisexual men, and 
transgender people; and 
(B) conduct a study on the solutions to the 
barriers individuals face in accessing PrEP 
medication and its associated services, such as 
HIV and other STI screening, especially among 
communities of color, gay and bisexual men, 
and transgender people. 
Æ 
VerDate Sep 11 2014 
01:16 Jun 26, 2018
Jkt 079200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR960.IH
HR960
lotter on DSKBCFDHB2PROD with BILLS